| 1 |
35330134 | Interaction Analysis of MRP1 with Anticancer Drugs Used in Ovarian Cancer: In Silico Approach. | 2022 Mar 7 |
2 |
| 2 |
31088908 | HIF Inactivation of p53 in Ovarian Cancer Can Be Reversed by Topotecan, Restoring Cisplatin and Paclitaxel Sensitivity. | 2019 Aug |
1 |
| 3 |
28373423 | New and Old Genes Associated with Topotecan Resistance Development in Ovarian Cancer Cell Lines. | 2017 Apr |
1 |
| 4 |
26692923 | FL118, a novel camptothecin analogue, overcomes irinotecan and topotecan resistance in human tumor xenograft models. | 2015 |
1 |
| 5 |
24694948 | Activity of a novel Hec1-targeted anticancer compound against breast cancer cell lines in vitro and in vivo. | 2014 Jun |
1 |
| 6 |
21309545 | Double-transduced MDCKII cells to study human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier. | 2011 Apr 4 |
1 |
| 7 |
21514634 | Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma. | 2011 Jul |
4 |
| 8 |
20460504 | Tyrosine kinase inhibitor gefitinib enhances topotecan penetration of gliomas. | 2010 Jun 1 |
1 |
| 9 |
18654741 | Involvement of P-glycoprotein, multidrug resistance protein 2 and breast cancer resistance protein in the transport of belotecan and topotecan in Caco-2 and MDCKII cells. | 2008 Nov |
1 |
| 10 |
18703021 | Induction of P-glycoprotein expression and function in human intestinal epithelial cells (T84). | 2008 Oct 1 |
2 |
| 11 |
16454695 | Topotecan is a substrate for multidrug resistance associated protein 4. | 2006 Jan |
2 |
| 12 |
16917872 | A novel MDR1 G1199T variant alters drug resistance and efflux transport activity of P-glycoprotein in recombinant Hek cells. | 2006 Dec |
4 |
| 13 |
16132345 | Human multidrug resistance associated protein 4 confers resistance to camptothecins. | 2005 Nov |
1 |
| 14 |
12089223 | Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. | 2002 Jul 1 |
2 |
| 15 |
10912951 | Growth inhibitory effect of a new camptothecin analog, DX-8951f, on various drug-resistant sublines including BCRP-mediated camptothecin derivative-resistant variants derived from the human lung cancer cell line PC-6. | 2000 Jun |
2 |
| 16 |
10604726 | Reversal of MDR1-associated resistance to topotecan by PAK-200S, a new dihydropyridine analogue, in human cancer cell lines. | 1999 Dec |
1 |
| 17 |
9553662 | High-dose topotecan with granulocyte-colony stimulating factor in fluoropyrimidine-refractory colorectal cancer: a phase II and pharmacodynamic study. | 1998 Feb |
6 |
| 18 |
9635842 | Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line. | 1998 May |
2 |
| 19 |
7931489 | Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia. | 1994 Oct |
1 |
| 20 |
1348448 | Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue. | 1992 Apr 15 |
3 |
| 21 |
1682041 | Camptothecin overcomes MDR1-mediated resistance in human KB carcinoma cells. | 1991 Nov 15 |
3 |